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The relationship between intestinal microbiota composition and acute graft-versus-host disease (GVHD) after
allogeneic blood/marrow transplantation (allo-BMT) is not well understood. Intestinal bacteria have long
been thought to contribute to GVHD pathophysiology, but recent animal studies in nontransplant settings
have found that anti-inﬂammatory effects are mediated by certain subpopulations of intestinal commensals.
Hypothesizing that a more nuanced relationship may exist between the intestinal bacteria and GVHD, we
evaluated the fecal bacterial composition of 64 patients 12 days after BMT. We found that increased bacterial
diversity was associated with reduced GVHD-related mortality. Furthermore, harboring increased amounts of
bacteria belonging to the genus Blautia was associated with reduced GVHD lethality in this cohort and was
conﬁrmed in another independent cohort of 51 patients from the same institution. Blautia abundance was
also associated with improved overall survival. We evaluated the abundance of Blautiawith respect to clinical
factors and found that loss of Blautia was associated with treatment with antibiotics that inhibit anaerobic
bacteria and receiving total parenteral nutrition for longer durations. We conclude that increased abundance
of commensal bacteria belonging to the Blautia genus is associated with reduced lethal GVHD and improved
overall survival.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite continuing improvements in outcomes of pa-
tients undergoing allogeneic blood/marrow transplantation
(allo-BMT), acute graft-versus-host disease (GVHD) con-
tinues to be a leading cause of mortality [1]. Current immune
suppression strategies are only partially effective at pre-
venting GVHD and simultaneously increase the risk for
infections and disease recurrence. Strategies that can reducedgments on page 1381.
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ty for Blood and Marrow Transplantation.GVHD but leave immune function intact may thus potentially
signiﬁcantly improve outcomes. One such strategy is to
target the complex community of microbes that reside
within our intestinal tracts, collectively termed the intestinal
microbiota.
A relationship between the microbiota and GVHD has
long been suspected but is still not well understood. Mice
transplanted in germ-free conditions [2] or treated with gut-
decontaminating antibiotics [3] develop less severe GVHD.
Clinical studies initially suggested a beneﬁt from near-total
bacterial decontamination [4,5] but later showed no clear
beneﬁt [6-8], and this approach was discontinued in the
early 1990s [9]. Partial gut decontamination continues to be
R.R. Jenq et al. / Biol Blood Marrow Transplant 21 (2015) 1373e13831374practiced, but little is known regarding optimal selection
of antibiotic regimens. One study found the addition of
metronidazole to ciproﬂoxacin led to a signiﬁcant reduction
in acute GVHD, suggesting that anaerobic bacteria may
contribute to GVHD pathogenesis [10].
More recent results, however, indicate that this approach
may not be ideal. Several studies have found that obligate
anaerobes in the intestine, in particular clostridial species, are
important mediators of intestinal homeostasis and prevent
inﬂammation by up-regulating intestinal regulatory T cells
[11]. In a recent study of 80 allo-BMT recipients at our center,
our group reported that increased intestinal bacterial diversity
at the time of engraftment was associated with improved
overall survival and reduced nonrelapse mortality [12].
Although we did not ﬁnd a signiﬁcant association between
bacterial diversity and GVHD in this study, this may have
been because the population was underpowered to detect
a difference in GVHD. Many of the patients had received a
T celledepleted allograft, which confers a much lower risk
of developing GVHD [13,14] and may have led to insufﬁcient
GVHD events to detect an effect of the microbiota.
In this study we focused on the outcome of GVHD by
studying patients who were most at risk. Using a prospec-
tively collected fecal specimen bank, we examined a popu-
lation of 115 allo-BMT patients from our institution who
received T cellereplete allografts. Here, we describe our
ﬁnding that bacteria in the intestinal tract from the genus
Blautia are associated with reduced mortality from GVHD.METHODS
Study Design and Oversight
Our participants were from a subset of patients prospectively enrolled in
a fecal collection protocol, where samples were collected during the initial
transplant hospitalization and stored in a biospecimen bank. Since 2009,
nearly all patients undergoing allo-BMT performed by the adult BMT service
at our center (age 18 and older) were approached to enroll, and the vast
majority of patients agreed to participate.
Patients who received conventional grafts (noneT cell depleted) and
had a fecal sample collected within 4 days of day 12 after allo-BMT were
included in this study. Patients who received ex vivo T celledepleted grafts
were speciﬁcally excluded, given their historically low rates of grades II to IV
acute GVHD of approximately 15%; notably, in this setting patients do not
receive any post-transplant GVHD prophylaxis [13,14]. In comparison,
in vivo T cell depletion with antithymocyte globulin administration is less
effective at reducing the incidence of GVHD in recipients of conventional
grafts, estimated at 28% in a large meta-analysis, with most patients still
receiving GVHD prophylaxis with calcineurin inhibitors [15]. Thus, in this
study we allowed inclusion of patients receiving antithymocyte globulin
given their continued substantial risk of developing acute GVHD. No
patients in the fecal specimen protocol received alemtuzumab for condi-
tioning or post-transplant cyclophosphamide during the study period.
Stool specimens were requested at least weekly over the course of the
transplant hospitalization. After collection, specimens were initially stored
at 4C. Within 24 hours, specimens were aliquoted into cryovials and stored
at 80C. The study was approved by the institutional review board at
Memorial Sloan Kettering Cancer Center. All study patients provided written
informed consent for biospecimen collection and analysis.
Patients included in this study were divided into cohorts 1 and 2,
determined by the sequencing platform used to analyze their fecal samples.
Selection of sequencing platform resulted from a combination of BMT date,
stool collection days, and number of samples from each patient. From 2009
through 2012, we sequenced using the Roche 454 platform (454 Life Sci-
ences, Branford, CT) samples from consecutive patients who met inclusion
criteria regarding number and timing of samples for studies previously
published [12,16]; these patients comprised cohort 1. Samples collected
from patients who did not meet inclusion criteria were stored but not
sequenced at the time. After 2013, we transitioned to the Illumina MiSeq
sequencing platform (Illumina, San Diego, CA). Patients with stored samples
who met inclusion criteria for the current study as well as additional pa-
tients transplanted in 2013 were included in cohort 2. Primary comparisons
performed in this study were within each of the 2 cohorts, and thus there
were no comparisons across cohort groups.Study Deﬁnitions
Acute GVHD was diagnosed clinically, conﬁrmed pathologically by
biopsy whenever possible, and classiﬁed according to International Bone
Marrow Transplant Registry criteria [17]. Late-onset acute GVHD, occurring
more than 100 days after transplantation [18,19], was included in the deﬁ-
nition of acute GVHD, whereas chronic GVHD in the absence of acute
features was not. Cases of GVHD were further characterized by treatment:
(1) topical steroids or budesonide, (2) systemic steroids (prednisone or
methylprednisolone, .5 mg/kg daily or higher), and (3) second-line therapy
in patients with steroid-refractory GVHD.
Cause of death was determined using a standard algorithm where
competing causes were prioritized in the following order: (1) primary dis-
ease recurrence, (2) graft failure, (3) GVHD, (4) infection, and (5) organ
failure. Thus, in patients without disease recurrence or graft failure, those
who were being treated for GVHD at the time of death were considered to
have succumbed to GVHD-related mortality, including those who died with
infections [20]. Deaths classiﬁed as non-GVHD treatment-related mortality
included patients who succumbed to graft failure, infection (in the absence
of acute GVHD therapy), and organ failure.
Disease risk was determined according to the American Society for
Blood and Marrow Transplantation Request for Information 2014 disease
classiﬁcation [21]. Conditioning intensity was assigned based on previously
established working deﬁnitions [22].
Antibiotic Categories
Antibiotics used during the transplant hospitalization were divided into
those that included signiﬁcant activity against anaerobic bacteria (piper-
acillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastatin, meropenem,
metronidazole, oral vancomycin, and clindamycin) and those with reduced
anaerobic activity in the intestinal tract (i.v. vancomycin, ceftriaxone, cefta-
zidime, cefepime, aztreonam, and trimethoprim-sulfamethoxazole) [23].
Transplantation Practices
As per our institutional practice, patients whose conditioning was more
intense than nonmyeloablative received prophylaxis with ciproﬂoxacin
(400 mg i.v. or 500 mg orally every 12 hours) and vancomycin (1 g i.v. every
12 hours) starting day 2 relative to BMT infusion [24]. Antibiotic prophy-
laxis against Pneumocystis carinii (trimethoprim-sulfamethoxazole, aero-
solized pentamadine, or atovaquone) was given at the discretion of the
transplant physician. Administration of total parenteral nutrition (TPN) was
considered on day 2 after transplant in patients with poor oral intake and
was discontinued upon oral recovery. Treatment of GVHD was at the
discretion of the transplant physician and generally involved topical corti-
costeroids for mild to moderate isolated skin GVHD, oral budesonide for
mild gastrointestinal GVHD, and systemic steroids for all other manifesta-
tions of GVHD, including liver and more severe skin and gastrointestinal
GVHD. Patients were also maintained on a nonsteroid immunosuppressant,
typically a calcineurin inhibitor, to allow eventual tapering of systemic
steroids. Patients refractory to systemic steroids received second-line
therapy at the discretion of the transplant physician.
Analysis of Specimens
For each stool specimen, DNA was puriﬁed using a phenol-chloroform
extraction technique with mechanical disruption (bead-beating) based on
a previously described protocol [25]. Samples from the ﬁrst 64-patient ﬂora
cohort were analyzed using the 454 GS FLX Titanium platform (454 Life
Sciences, Branford, CT) to sequence the V1-V3 region of the bacterial 16S
rRNA gene. Samples from the second 51-patient ﬂora cohort were subse-
quently analyzed using the Illumina MiSeq platform to sequence the V4-V5
region of the 16S rRNA gene. Sequence data were compiled and processed
using mothur version 1.34 [26], screened and ﬁltered for quality [27], and
then classiﬁed to the species level [28] using a modiﬁed form of the
Greengenes reference database [29]. Microbial diversity was quantiﬁed
using the inverse Simpson index [30] and the Shannon diversity index [31]
of operational taxonomic units with 97% similarity [32]. Taxonomic abun-
dance comparisons were performed to identify biomarkers of GVHD-related
mortality using linear discriminant analysis effect size analysis [33], using a
logarithmic linear discriminant analysis cut-off of 2.0 as described in the
original article by the developers [33]. Data from this study have been stored
in the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra).
Quantiﬁcation of 16S rRNA copies was performed using qPCR on DNA
extracted from fecal specimens as previously described [34].
Statistical Analysis
The incidence of acute GVHD and GVHD-related mortality was esti-
mated using cumulative incidence functions, treating relapse and death
unrelated to GVHD as competing events, and compared across factors using
Gray’s test. Comparison across Blautia abundance was done ﬁrst in a cohort
Table 1
Clinical Characteristics of Allo-BMT Patients Transplanted at Memorial Sloan Kettering Cancer Center with Stool Samples Collected Day 12 after BMT Included in
an Identiﬁcation and Validation Cohort
Cohort 1 Cohort 2
Dates of transplant September 2009 to October 2012 August 2011 to August 2013
Age, yr 25-70, median 53 26-75, median 50
Gender Female 38%, male 62% Female 32%, male 69%
Primary malignancy NHL 38%, AML 38%, ALL 9.4%, Hodgkin disease 6.3%,
CLL 6.3%, MDS 3.1%
NHL 35%, AML 37%, ALL 12%, Hodgkin disease 3.9%,
CLL 7.8%, MDS 3.9%
Disease risk High 45%, intermediate 36%, low 19% High 35%, intermediate 27%, low 37%
Graft source Peripheral blood 55%, cord blood 42%, bone marrow 3.1% Peripheral blood 57%, cord blood 39%, bone marrow 3.9%
Donor relationship and HLA Sibling identical (29%), unrelated identical (22%),
unrelated nonidentical (48%)
Sibling identical (24%), unrelated identical (29%),
unrelated nonidentical (47%)
Conditioning intensity Standard intensity myeloablative 23%, reduced-intensity
myeloablative 44%, nonmyeloablative 33%
Standard intensity myeloablative 14%, reduced-intensity
myeloablative 57%, nonmyeloablative 29%
Stool sample collection day þ8 to þ16, median þ12 þ8 to þ16, median þ12
NHL indicates non-Hodgkin lymphoma; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; MDS,
myelodysplastic syndrome.
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bilities were estimated using Kaplan-Meier methodology and compared
using the log rank test. Incidence and overall survival data are presented
relative to the time of BMT, but patient cohorts were analyzed relative to theA B
C
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Figure 1. Changes in the intestinal ﬂora are associated with differences in GVHD-rela
index after composition analysis of stool samples from cohort 1 performed by 16S gen
analyzed for cumulative incidence of GVHD-related mortality. (B) Associations of bac
discriminant analysis effect size analysis. Position along the vertical axis indicates stat
Blautia abundance (.05% in both) and analyzed for incidence of GVHD-related mortallandmark of day 12, the median time of stool collection. We note that no
patients in the study died or developed GVHD before day 16. Comparison of
the risk of acute GVHD and GVHD-related mortality after adjusting for
clinical factors was performed using Cox regression. A receiver operating .05
P = .04
ted mortality. (A) Bacterial diversity was quantiﬁed using the inverse Simpson
e sequencing. Patients were stratiﬁed by the median diversity index value and
terial genera with GVHD-related mortality outcomes were quantiﬁed by linear
istical signiﬁcance. (C) Patients from cohorts 1 and 2 were stratiﬁed by median
ity.
Figure 2. (A) Association of Blautia abundance and outcomes after allo-BMT. Patients from the 2 ﬂora cohorts were combined and stratiﬁed by Blautia abundance
below or above .05% and evaluated for the indicated outcomes; similar results were seen for each individual cohort (not shown). (B) Blautia abundance (left), survival,
and cause of death (right) are indicated for individual patients from 2 cohorts combined, ranked by Blauita abundance.
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criminators for 1-year GVHD-related mortality [35]. A Blautia abundance
trend curve was constructed using LOESS (locally weighted scatter plot
smooth) local regression to estimate the marginal trend of Blautia abun-
dance over time with a corresponding 95% conﬁdence interval (CI). Com-
parisons of bacterial abundancewere performed using theMann-Whitney U
for unpaired 2-way tests, Kruskal-Wallis for 3-way tests, and Wilcoxon
signed-rank for paired tests. In all analyses statistical signiﬁcance was
deﬁned as P < .05 based on a 2-sided test. Statistical analyses were per-
formed using R version 3.1.0 (The R Foundation for Statistical Computing,
Vienna, Austria).Table 2
Association of Various Bacterial Taxa with GVHD-Related Mortality in
Patients from the Cohorts Combined
Classiﬁcation
Level
Bacterial Taxon Median
Abundance
GVHD-Related
Mortality
Log Rank P
Genus Blautia .05% .004
Genus Enterococcus 1.32% .8
Genus Bacteroides .02% .5
Genus Lactobacillus .23% .3
Genus Veillonella .03% .8
Family Lachnospiraceae .21% .02
Order Clostridiales 2.92% .02
Class Clostridia 3.51% .02
Phylum Firmicutes 95.39% .7
Suborder Clostridial clusters
IV, XIVa, and XVIII
.31% .09
P < .05 are depicted in bold.RESULTS
Intestinal Flora Diversity Near Day 12 Is Associated with
Reduced GVHD-Related Mortality
Our group recently reported that increased bacterial
diversity at the time of engraftment after allo-BMT was
associated with improved overall survival and reduced
transplant-related mortality, but in that heterogeneous
patient population we did not ﬁnd an association between
diversity and GVHD [12]. For the current study, we began by
asking if bacterial ﬂora diversity was associated with lethal
GVHD in amore uniform population of patients at higher risk
for developing GVHD. We used prospectively banked stool
samples collected from patients who underwent allo-BMT at
our center. We chose to target day 12, reasoning that this
time point was late enough for stool specimens to reﬂect
changes induced by the transplant hospitalization, including
antibiotic exposures, and still preceded the development of
GVHD in all patients. We identiﬁed 64 patients in cohort
1 who, after conventional allo-BMT without T cell depletion,
had provided a stool sample after BMT infusion and before
hospital discharge (collected days, 8 to 16; median, day 12;
clinical characteristics summarized in Table 1). We analyzed
the ﬂora composition of these stool samples using the454 platform and followed patients clinically for develop-
ment of GVHD-related mortality. Importantly, our institu-
tional practice regarding bacterial prophylaxis is to
administer ciproﬂoxacin and i.v. vancomycin prophylaxis
starting day 2. We have found that this antibiotic prophy-
laxis practice has a relatively modest impact on intestinal
ﬂora diversity [12], which is in agreement with the phar-
macokinetics and biodistribution of i.v. vancomycin [36].
To evaluate the association between ﬂora diversity and
GVHD-related mortality, we used a typical approach to
evaluate potential biomarkers, where patients are stratiﬁed
by the median value into 2 equal-sized groups and the
incidence of the outcome of interest is compared [37]. We
found that increased bacterial diversity, quantiﬁed by the
inverse Simpson index, was associated with reduced GVHD
lethality (Figure 1A, P ¼ .005).
Figure 3. Association of Blautia abundance with clinical acute GVHD. (A) Patients were stratiﬁed by Blautia abundance below or above .05% and evaluated for
development of the indicated severity grades of acute GVHD as well as acute GVHD that required systemic therapy with corticosteroids. (B) Patients were evaluated
for development of acute GVHD in typical target organs.
Table 3
Subgroup Analysis of Patients from the Cohorts Combined Examining the
Relationship Between Blautia Abundance and GVHD-Related Mortality
Subgroup No. of Cases
(Blautia Low)
No. of Cases
(Blautia High)
GVHD-Related
Mortality
Log Rank P
Myeloablative
conditioning
13 9 .1
Reduced-intensity
conditioning
27 30 .3
Nonmyeloablative
conditioning
18 18 .02
PBSC graft 31 33 .006
Cord blood graft 24 23 .2
PBSC indicates peripheral blood stem cell.
P < .05 are depicted in bold.
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12 Is Associated with Reduced Acute GVHD Requiring
Systemic Immune Suppression
To identify bacterial subsets associated with GVHD-
related mortality, we focused on bacterial phylogeny at the
genus level, which is generally the most speciﬁc level at
which 16S deep sequencing still provides reliable classiﬁca-
tion. Our approach involved ﬁrst identifying bacterial genera
potentially associated with GVHD-related mortality using a
taxonomic discovery analysis, then evaluating candidate
genera for their association with the incidence of GVHD-
related mortality, and ﬁnally evaluating for reproducibility
of observed associations in an additional independent cohort
of patients from the same institution. Beginning with taxo-
nomic discovery analysis of bacterial genera, we found that
bacteria belonging to the genus Blautia were most signiﬁ-
cantly associated with reduced GVHD-related mortality
(Figure 1B, P ¼ .01). The Blautia genus notably includes
anaerobic intestinal commensal organisms within the bac-
terial class Clostridia [38,39]. The genus Veillonella, in
turn, was associated with increased GVHD-related mortality
(P ¼ .047).We then evaluated the association of Blautia and Veillo-
nella abundance with GVHD-related mortality, stratifying
patients by the median abundance (.05% and .04%, respec-
tively). We found that patients with higher Blautia abun-
dance had reduced GVHD-related mortality (Figure 1C,
Figure 4. Identifying potential determinants of Blautia abundance in allo-BMT patients. (A) Left: Blautia abundances in all available stool samples from both ﬂora
cohorts. An abundance trend was constructed using moving average ﬁltering (solid blue line; 95% conﬁdence intervals shown in gray). Middle and Right: Serial fecal
sample composition analysis from 2 representative patients. Vertical bars indicate composition of fecal microbiota by the indicated taxa. Horizontal bars indicate
antibiotic and TPN exposures. Flora composition and time courses of antibiotic and TPN exposure for all patients are shown in Supplemental Figure 2. IV indicates
intravenous; PO, oral; pip-tazo, piperacillin-tazobactam; tmp-smx, trimethoprim-sulfamethoxazole. (B) Patients were subsetted by exposure to antibiotics with
anaerobic coverage before sample collection and duration of TPN therapy, and Blautia abundance was evaluated. Horizontal bars indicate median Blautia abundance.
(C) A subset of patients who were not exposed to antibiotics with anaerobic coverage before sample collection were further subsetted by duration of TPN therapy and
evaluated for Blautia abundance in a stool sample before day 12 and from day 12.
R.R. Jenq et al. / Biol Blood Marrow Transplant 21 (2015) 1373e13831378P ¼ .04), whereas Veillonella was not signiﬁcantly associated
with GVHD-related mortality (data not shown, P ¼ .16). We
repeated this analysis in cohort 2, which included 51 inde-
pendent patients from the same institution who provided
fecal samples analyzed on the MiSeq deep-sequencing plat-
form (clinical characteristics summarized in Table 1). Thiscohort reproduced our prior results, where a Blautia abun-
dance above the median (which, similar to cohort 1, was
.05%) was associated with less GVHD lethality (Figure 1C,
P ¼ .04). In this second cohort, Veillonella again was not
associated with GVHD-related mortality (data not shown,
P ¼ .5).
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12 Is Associated with Improved Overall Survival
By evaluating the combined cohorts, we found that
Blautia abundance was strongly associated with improved
overall survival after allo-BMT (P < .001). This could largely
be explained by reduced GVHD-related mortality (P ¼ .004)
and to a lesser degree reduced relapse-related mortality
(P ¼ .03), with no difference in non-GVHD treatment-related
mortality (Figure 2A). Similar results were observed when
cohorts were analyzed separately (data not shown). Blautia
abundance, survival, and cause of death are depicted for each
individual patient in Figure 2B, demonstrating that many of
the GVHD-related deaths occurred in patients with lower
Blautia abundance.
Some of the GVHD-related deaths in this patient popu-
lation occurred somewhat later thanwould be expected after
allo-BMT, with 9 of 17 events occurring after day 180. In these
patients, most developed acute GVHD during the taper of
immune suppression (median day after BMT, 41; range, 21 to
80). Donor lymphocyte infusion, commonly performed for
disease relapse and a potential risk factor for late acute
GVHD, was administered to 3 patients but did not contribute
to acute GVHD in these patients. Chronic GVHD, which can
occur after acute GVHD or develop de novo, was diagnosed
in only 1 patient who experienced GVHD-related mortality
and thus was also not a signiﬁcant contributor to late GVHD-
related mortality in this study.
Having demonstrated an association of Blautia abundance
with GVHD-related mortality using median Blautia abun-
dance to stratify patients, we next sought to compare this
threshold with other potential cut-offs of Blautia abundance.
We generated a receiver operating characteristic curve
(Supplemental Figure 1A), which had an estimated area
under the curve of .72 (95% CI, .52 to .93), further suggesting
that Blautia abundance may have utility as a biomarker of
GVHD-related mortality. With a sensitivity of .51 and speci-
ﬁcity of .84, the receiver operating characteristic curve sup-
ported the use of the median to stratify patients at high risk
for GVHD-related mortality.
A potential limitation of 16S rRNA deep sequencing is the
lack of absolute abundance information regarding bacterial
subtypes. To determine the absolute abundance of Blautia
16S rRNA genes in fecal samples, we normalized the relative-
abundance measurements from deep sequencing to the
absolute abundance of 16S rRNA quantiﬁed by real-time PCR.
We had adequate DNA to perform this for most patients
(84 of 115, Supplemental Table 1) and found that absolute
Blautia abundance, similar to relative Blautia abundance, was
associated with reduced GVHD-related mortality (P ¼ .01,
Supplemental Figure 1B).
We also searched for an association of GVHD-related
mortality with other bacterial genera. Because increased
Enterococcus may be associated with GVHD [40], we eval-
uated if Enterococcus, or potentially beneﬁcial bacterial
genera (Lactobacillus [41,42] and Bacteroides [43]), were
associated with GVHD-related mortality in our patient
population. Our results indicated that none of these bac-
terial genera was associated with GVHD-related mortality
in the combined cohorts (P ¼ .8, P ¼ .5, and P ¼ .3,
respectively, Table 2).
We next asked if bacterial subtypes related to Blautiawere
associatedwith reduced lethal GVHD. Bacteria from thegenus
Blautia are classiﬁedas follows: family Lachnospiraceae, order
Clostridiales, class Clostridia, and phylum Firmicutes [38].
Stratiﬁcation of patients by abundance of bacteria fromLachnospiraceae, Clostridiales, and Clostridia all demon-
strated associations with a reduced incidence of lethal GVHD
(P¼ .02, P¼ .02, and P¼ .02, respectively, Table 2), suggesting
that members of Blautia, and potentially its close relatives,
contribute aprotectiveeffect against lethalGVHD. Inclusionof
more distant relatives by examining all Firmicutes, however,
resulted in loss of the association (P ¼ .7, Table 2).Abundance of Bacteria from the Genus Blautia Near Day
12 Is Associated with Reduced Need for Acute GVHD
Treatment
We then asked if Blautia abundance was associated with a
reduction in the clinical severity of acute GVHD. We found
that the association between Blautia abundance and reduced
incidence of acute GVHD grades II to IV did not reach
statistical signiﬁcance (P ¼ .1, Figure 3A), and there was no
association with acute GVHD grades III to IV (P ¼ .5,
Figure 3A). Blautia abundance, however, was associated with
reduced development of acute GVHD that required treat-
ment with systemic corticosteroids or was steroid refractory
(P ¼ .01, Figure 3A), suggesting that loss of Blautia is associ-
ated with acute GVHD that will not respond to topical cor-
ticosteroids or budesonide alone. Regarding classical acute
GVHD target organs, increased Blautia abundance was not
associated with skin GVHD or upper gut GVHD (Figure 3B).
The association with reduced lower gut GVHD was not
statistically signiﬁcant (P ¼ .1, Figure 3B), whereas that with
reduced liver GVHD was signiﬁcant (P ¼ .02, Figure 3B),
although the number of events was small.Abundance of Bacteria from the Genus Blautia Is Most
Associated with Reduced GVHD Lethality in Patients
Receiving Nonmyeloablative Conditioning and Peripheral
Blood Stem Cell Allografts
We then evaluated the association between Blautia and
lethal GVHD in patients divided into subgroups by condi-
tioning intensity or by graft source. Blautia was most asso-
ciated with reduced lethal GVHD in patients who received
nonmyeloablative conditioning (P ¼ .02, Table 3), whereas
the association in patients receiving myeloablative and
reduced-intensity conditioning did not reach statistical
signiﬁcance (P ¼ .1 and P ¼ .3, Table 3). In patients divided by
graft source, those who received peripheral blood stem cell
allografts showed an association between Blautia abundance
and reduced lethal GVHD (P ¼ .006, Table 3), whereas in
those receiving umbilical cord blood stem cell grafts the
association did not reach statistical signiﬁcance (P ¼ .2,
Table 3).Blautia Abundance Is Independent of Known Clinical
Acute GVHD Risk Factors
To determine if Blautia abundance provides additional
prognostic information to GVHD outcomes, we investigated
potential associations between Blautia abundance and
known risk factors for acute GVHD [44-46]. We found that
patient age, performance status, disease risk, cytomegalo-
virus status, graft source, donor/patient gender, conditioning
intensity, antithymocyte globulin administration, or GVHD
prophylactic regimen were not associated with Blautia
abundance (Supplemental Table 2). Although limited by
small numbers, patients of an Asian or Hispanic background
appeared to have lower abundance of Blautia.
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Abundance During Allo-BMT Hospitalization
To better understand the heterogeneity in Blautia abun-
dance in our patient population, we attempted to identify
determinants of Blautia abundance. An analysis of all stool
samples collected from both ﬂora cohorts showed that most
patients had relatively abundant amounts of Blautia upon
admission for transplant hospitalization, with a median
abundance > .1 (10%) (Figure 4A). Some patients retained
their Blautia throughout their hospital course, whereas
others rapidly dropped Blautia levels during hospitalization
(Figure 4A and Supplemental Figure 2). We found that pa-
tients not exposed to antibiotics containing increased
anaerobic coverage were more likely to have increased levels
of Blautia (P ¼ .01, Figure 4B), a ﬁnding that was expected
given that Blautia is an obligate anaerobe. Intestinal ﬂora
composition analyses for individual patient samples along
with antibiotic exposures are provided in Supplemental
Figure 2.
We then asked if conditioning intensity was also associ-
ated with Blautia abundance but found this was not the case
(P ¼ .5, Supplemental Table 2). Interestingly, however, use of
TPN was associated with changes in Blautia abundance.
Because of nausea and mucositis after conditioning, allo-
BMT patients commonly experience a prolonged period of
signiﬁcantly reduced oral intake and are treated with sup-
plementary TPN. Because initiation of TPN at our institution
is considered at the earliest on day 2 and stool samples were
on average collected on day 12, we compared patients with
TPN use of less than 10 days duration (indicating delayed,
interrupted, or discontinued TPN therapy) with those with
TPN use of 10 days or more. We found increased levels of
Blautia in patients who received shorter courses of TPN
therapy (Figure 4B), and TPN duration was associated with
loss of Blautia even in patients who avoided treatment with
anaerobe-active antibiotics (Figure 4C). TPN exposures for
individual patients are provided in Supplemental Figure 2.
Blautia Abundance Remains Associated with GVHD-
Related Mortality after Adjusting for Potential Clinical
Confounders
We ﬁnally performed univariate and multivariate ana-
lyses to determine if the association of Blautia abundance
with GVHD outcomes was driven by potential clinical
confounders. Given the limited numbers of GVHD-related
mortality events, we restricted our multivariate analysis to
2 factors, in addition to Blautia abundance. To identify po-
tential confounders, we examined a variety of clinical factors
previously shown to be linked to GVHD. This approach
identiﬁed the GVHD prophylaxis regimen as the only statis-
tically signiﬁcant factor for GVHD-related mortality; specif-
ically, patients who received cyclosporine and
mycophenolate had higher event rates (P ¼ .044). This
regimen is the standard GVHD prophylaxis for patients
receiving cord blood grafts at our center, and indeed,
recipients of cord grafts showed a similar trend toward
higher GVHD-related mortality (P ¼ .062). An additional
factor that almost reached statistical signiﬁcance was expo-
sure to antibiotics with anaerobic coverage (P ¼ .055). We
thus generated a model adjusting for 2 factors, graft source
and exposure to anaerobic antibiotics, and found that Blautia
abundance remained associated with both GVHD-related
mortality (hazard ratio, .18; 95% CI, .05 to .63; P ¼ .007) and
clinical GVHD treated with systemic steroids (hazard ratio,
.3; 95% CI, .14 to .64; P ¼ .002). Finally, we tested theassociation of Blautia abundance with relapse-related mor-
tality after adjusting for 2 factors, disease risk and graft
source, and found that the association with Blautia abun-
dance no longer reached statistical signiﬁcance (P ¼ .055).
DISCUSSION
In this study we found that in allo-BMT recipients’
intestinal ﬂora diversity was associated with reduced GVHD
lethality. Furthermore, the bacterial genus from stool sam-
ples most associated with reduced GVHD-related mortality
was Blautia in 2 independent cohorts from the same insti-
tution. Patients with more Blautia also showed a reduced
incidence of acute GVHD that required treatment with
systemic corticosteroids or was steroid refractory, as well as
improved overall survival. Surprisingly, despite the associa-
tionwith GVHD-related mortality, Blautia abundance did not
distinguish the incidence of acute GVHD grades II to IV or
even grades III to IV, which has been shown to identify
patients less likely to respond to steroids, leading to poorer
survival [47]. However, a subpopulation of patients who
initially presentedwith grade II acute GVHD but nevertheless
fared poorly has been described, and these patients may be
better identiﬁed by novel GVHD grading systems [47] or by
novel biomarkers [48]. Further investigations in additional
larger patient cohorts may determine if Blautia abundance
can similarly supplement the prognostic utility of clinical
acute GVHD grading.
This study has several important limitations. First,
because our results are from a single center, results may not
be generalizable to other centers with different patient
populations, in particular, different antibiotic practices.
Additionally, although we have found that Blautia is associ-
ated with GVHD-related mortality, this was identiﬁed in an
exploratory manner and conﬁrmed in a relatively small
validation cohort. Furthermore, we have not demonstrated
causality, that is, that the presence of Blautia directly protects
against lethal GVHD. It is possible that Blautia is predominant
member of a larger group of bacteria that can mediate
beneﬁcial anti-inﬂammatory effects and disappear as a
consortium. Atarashi et al. [11] reported that administering a
mixture of 17 Clostridia isolates can reduce intestinal
inﬂammation in mice by increasing inﬁltration of the large
intestine with regulatory T cells. Consistent with this, we
found that the abundance of bacteria from the class Clos-
tridia, which includes Blautia, was associated with reduced
GVHD-related mortality in our patients. A beneﬁcial anti-
inﬂammatory association of Blautia has also been observed
in other clinical settings, including colorectal cancer [49],
inﬂammatory pouchitis after ileal pouch-anal anastomosis
[49], and liver cirrhosis [50], where Blautiawas one of several
subtypes of bacteria associated with improved outcomes.
One question that arises is how a patient’s Blautia abun-
dance on day 12 after allo-BMT could biologically have an
impact on whether months later he or she develops symp-
toms of acute GVHD or as late as a year later succumbs acute
GVHD-related mortality. There are precedents, however; low
serum cyclosporine concentrations in the ﬁrst week after
allo-BMT were found to be associated with later develop-
ment of acute GVHDwith onset largely occurring after day 30
[51]. Additionally, serum levels of the biomarker ST2 levels
on day 14 were found to be associated with a 6-month
nonrelapse mortality [48]. Together, these studies suggest
that clinical conditions early post-BMT may affect the initi-
ation of GVHD and modulate its eventual severity, although
this can in some cases take months to fully manifest, perhaps
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administration of immune suppressants in the forms of
GVHD prophylaxis and therapy.
Interestingly, although our results indicate that Blautia is
associated with reduced GVHD suggesting a link with
immune suppression, Blautia was not associated with
increased relapse-related mortality. Indeed, we detected an
association of Blautia with a reduction in relapse-related
mortality, although this no longer reached signiﬁcance in
ourmultivariate analysis. One explanation is that Blautiamay
be associated with a localized anti-inﬂammatory effect,
primarily in the intestinal tract, without systemic immune
suppression that could hinder a graft-versus-tumor effect.
This possibility is supported by the absence of an association
with skin GVHD. Together, these data suggest that targeting
the intestinal microbiota may allow for reduced intestinal
GVHD without simultaneously increasing the risk for
malignant relapse.
In our subgroup analyses, we found associations between
Blautia and GVHD outcomes in patients who received non-
myeloablative conditioning and in patients who received
peripheral blood stem cell allografts, but these associations
did not reach signiﬁcance in other patient subgroups who
received more intense conditioning or received cord blood
grafts. Limitations in sample size may have contributed to
this, and larger studies are likely required to evaluate the
association of Blautia with GVHD outcomes in allo-BMT
subgroups. In this study, patients undergoing increased
conditioning intensity experienced higher rates of treatment
with antibiotics and TPN, as did patients receiving cord blood
grafts. It is possible that an accumulation of risk factors for
microbiota injury led to reduced heterogeneity in certain
subgroups, and as a result the ability of Blautia abundance to
discriminate patients with GVHD outcomes was reduced.
By characterizing the abundance of Blautia in our patients
over the course of their transplant hospitalization, we found
that most patients initially had relatively large amounts of
Blautia that were dramatically lost during their hospital
course. Established risk factors for GVHDwere not associated
with changes in Blautia abundance, but 2 clinical risk factors
were associated with loss of Blautia: treatment with antibi-
otics with increased anaerobic coverage and prolonged
administration of TPN. Although conditioning intensity and
duration of TPN necessity are known to be associated [52],
we found no signiﬁcant association between conditioning
intensity and Blautia abundance. This suggests that mucositis
and/or poor oral nutrition may contribute to loss of Blautia
more directly than intense conditioning. Corroborating this
are ﬁndings in mouse models that myeloablative condition-
ing is associated with only mild perturbations in ﬂora
composition, in comparison with larger perturbations char-
acterized by loss of Clostridiales seen in both mice and
humanswith the onset of GVHD, a potent inducer of anorexia
[42]. A pattern of loss of members of Clostridiales, including
Roseburia, Faecalibacterium, Ruminococcus, and Blautia spe-
cies, can similarly be observed in volunteers placed on high-
protein and low-carbohydrate diets [53] or on diets derived
entirely from animal products [54]. Alternatively, epithelial
damage due to conditioning-induced mucositis could also
potentially result in changes in ﬂora composition via changes
in expression of antimicrobial molecules produced by in-
testinal epithelium [55].
A possibility raised by this study is that clinical strategies
to prevent damage to the intestinal microbiota, in particular
to preserve obligate anaerobic bacteria such as Blautia, maybe worth investigating in an effort to improve clinical
outcomes for allo-BMT patients. Potential strategies include
avoidance of antibiotics that suppress anaerobic members of
the commensal ﬂora or encouraging oral nutrition to
supporting anaerobic populations. Interestingly, a study
from Seguy et al. [56] in 2006 reported that treating patients
with enteral feeding led to a beneﬁt in overall survival and
reduced rates of acute GVHD grades III to IV and deaths due
to infection. In the context of our ﬁndings, these results may
indicate that intestinal commensals could mediate some
of the beneﬁts of enteral nutrition after allo-BMT. Choosing
less intense conditioning regimens may also help patients
maintain oral nutrition and boost Blautia abundance; indeed,
multicenter registry data indicate that less intense
conditioning regimens are associated with reduced acute
GVHD [45].
In conclusion, we have shown that the composition of the
intestinal ﬂora, in particular the abundance of anaerobic
bacteria from the genus Blautia, can be used as a novel
prognostic indicator for GVHD-related mortality. Further
studies will need to be performed to determine if this ﬁnding
holds true at other institutions. Additionally, studies to
evaluate the potential impact of Blautia and related bacteria
on the pathophysiology of GVHD arewarranted, as are efforts
to develop strategies to support anaerobic intestinal com-
mensals in patients who undergo allo BMT.
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